Renaissance Technologies LLC Sells 211,386 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV)

Renaissance Technologies LLC decreased its position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV - Free Report) by 36.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 363,400 shares of the company's stock after selling 211,386 shares during the period. Renaissance Technologies LLC owned about 0.43% of Verve Therapeutics worth $2,050,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Geode Capital Management LLC increased its position in Verve Therapeutics by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company's stock worth $9,172,000 after purchasing an additional 25,093 shares during the period. Trexquant Investment LP lifted its holdings in shares of Verve Therapeutics by 14.5% during the 4th quarter. Trexquant Investment LP now owns 635,847 shares of the company's stock valued at $3,586,000 after purchasing an additional 80,345 shares in the last quarter. Wellington Management Group LLP boosted its stake in Verve Therapeutics by 4.2% in the 4th quarter. Wellington Management Group LLP now owns 361,498 shares of the company's stock worth $2,039,000 after purchasing an additional 14,469 shares during the period. Barclays PLC boosted its holdings in Verve Therapeutics by 139.8% during the third quarter. Barclays PLC now owns 222,919 shares of the company's stock worth $1,079,000 after purchasing an additional 129,944 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Verve Therapeutics by 2.4% in the 4th quarter. Bank of New York Mellon Corp now owns 220,502 shares of the company's stock valued at $1,244,000 after purchasing an additional 5,262 shares during the last quarter. Institutional investors and hedge funds own 97.11% of the company's stock.

Wall Street Analysts Forecast Growth

VERV has been the subject of several research reports. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. HC Wainwright upped their price objective on Verve Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research note on Monday, April 14th. Canaccord Genuity Group raised their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a report on Tuesday, April 15th. Guggenheim lifted their price objective on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Finally, William Blair reiterated an "outperform" rating on shares of Verve Therapeutics in a report on Friday, February 21st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $25.75.

Verve Therapeutics Trading Down 0.1 %

Shares of NASDAQ:VERV traded down $0.01 on Thursday, reaching $5.67. 628,501 shares of the company traded hands, compared to its average volume of 1,773,379. The stock has a market capitalization of $505.00 million, a P/E ratio of -2.29 and a beta of 1.86. The business's 50-day simple moving average is $5.22 and its 200 day simple moving average is $5.95. Verve Therapeutics, Inc. has a 52 week low of $2.86 and a 52 week high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $13.08 million for the quarter, compared to analysts' expectations of $3.94 million. Sell-side analysts expect that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.